- Email: [email protected]
4912094 Modified lipopolysaccharides and process of preparation
New Patents Glycoprotein (GPIR) the ribosome-inhibiting activity of the native GPIR and having a proIongedaction in vivo which is obtained by oxidation of its osidi~ units by the action of periodate ions, and simulthneous blocking of the oxidation product by formation of a Schiff's base with a suitable primary amine. Said modified glycoprotein may be coupled to an antibody or a fragment thereof in order to form an immunotoxin.
4911912 RIBOSOME-INACTIVATING G L Y C O P R O T E I N S , M O D I F I E D BY OXIDATION OF THEIR OSIDIC UNITS AND REDUCTION, AND IN VIVO PROLONGED-ACTION IMMUNOTOXINS CONTAINING SUCH A GLYCOPROTEIN Pierre Casellas, Bernard Bourrie, Xavier Canat, Montpellier, France assigned to Sanofi Glycoprotein (GPIR) having the ribosomeinhibitingactivity of the native GPIR and having a prolonged-action in vivo which is obtained by oxidation of its osidic units by the action of periodate ions, and simultaneous reduction with cyanoborohydride ions. Said modified glycoprotein may be coupled to an antibody or a fragment thereof in order to form an immunotoxin having a prolonged-action in vivo.
4911918 ORAL COMPOSITION CONTAINING STABILIZED ANTIBODY Tatsu Kiyoshige, Yasuo Kikuchi, Hadano, Japan assigned to Lion Corporation An oral composition for preventing periodontal diseases through suppression of the colonization of causative bacteria of periodontal diseases comprises an antibody obtained by immunizing a mammal with at least one antigen selected from the group consisting of periodontal causative bacteria, their pilus and capsule fractions, and aluminum hydroxide for stabilizing said antibody.
xxi
4912030 VIRAL ISOLATES AND THEIR USE IN DIAGNOSIS Robin Weiss, Richard Tedder, Rachanee Cheingsong-Popov, Bridget Ferns, London, United Kingdom assigned to Institute of Cancer Research Samples e.g. transfusion blood, are assayed for antibodies to retroviruses, e.g. AIDS virus, using an insolubilized antigen comprising retrovirus antigens bound to globulin, the globulin itself being bound to an inert solid support; and an immunoglobulin which contains specific antibody to the retrovirus antigens and which is labelled with a revealing label, and the soluble phase is then separated from the insoluble phase and the quantity of revealing label associated with either the soluble or the insoluble phase determined. The sue of labelled antibody in competition with test sera for binding on the insolublized antigen permits better identification of antibody containing specimens. The retroviruses may be a human T-lymphotropic retrovirus HTLV-I, II or III or a new retrovirus isolate CBL-I etiologically related to AIDS.
4912094 MODIFIED LIPOPOLYSACCHARIDES AND PROCESS OF PREPARATION Kent Myers, Alex T Truchot assigned to Ribi ImmunoChem Research Inc Modified lipopolysaccharides, particularly de3-0-acylated monophosphoryl lipid A and de-30-acylated diphosphoryl lipid A, are provided by an alkaline hydrolysis under controlled conditions which removes only the betahydroxymyristic acyl residue that is ester-linked to the reducing-end glucosamine at position 3. The modified products are less endotoxic and maintain their antigenic and immunostimulating properties.
4912136 USES OF A SUBSTITUTED 2-PHENOXYPHENYLACETIC A C I D AS AN IMMUNOSUPPRESSANT DRUG Elizabeth M Wood, Dundee, United Kingdom
4911912 RIBOSOME-INACTIVATING G L Y C O P R O T E I N S , M O D I F I E D BY OXIDATION OF THEIR OSIDIC UNITS AND REDUCTION, AND IN VIVO PROLONGED-ACTION IMMUNOTOXINS CONTAINING SUCH A GLYCOPROTEIN Pierre Casellas, Bernard Bourrie, Xavier Canat, Montpellier, France assigned to Sanofi Glycoprotein (GPIR) having the ribosomeinhibitingactivity of the native GPIR and having a prolonged-action in vivo which is obtained by oxidation of its osidic units by the action of periodate ions, and simultaneous reduction with cyanoborohydride ions. Said modified glycoprotein may be coupled to an antibody or a fragment thereof in order to form an immunotoxin having a prolonged-action in vivo.
4911918 ORAL COMPOSITION CONTAINING STABILIZED ANTIBODY Tatsu Kiyoshige, Yasuo Kikuchi, Hadano, Japan assigned to Lion Corporation An oral composition for preventing periodontal diseases through suppression of the colonization of causative bacteria of periodontal diseases comprises an antibody obtained by immunizing a mammal with at least one antigen selected from the group consisting of periodontal causative bacteria, their pilus and capsule fractions, and aluminum hydroxide for stabilizing said antibody.
xxi
4912030 VIRAL ISOLATES AND THEIR USE IN DIAGNOSIS Robin Weiss, Richard Tedder, Rachanee Cheingsong-Popov, Bridget Ferns, London, United Kingdom assigned to Institute of Cancer Research Samples e.g. transfusion blood, are assayed for antibodies to retroviruses, e.g. AIDS virus, using an insolubilized antigen comprising retrovirus antigens bound to globulin, the globulin itself being bound to an inert solid support; and an immunoglobulin which contains specific antibody to the retrovirus antigens and which is labelled with a revealing label, and the soluble phase is then separated from the insoluble phase and the quantity of revealing label associated with either the soluble or the insoluble phase determined. The sue of labelled antibody in competition with test sera for binding on the insolublized antigen permits better identification of antibody containing specimens. The retroviruses may be a human T-lymphotropic retrovirus HTLV-I, II or III or a new retrovirus isolate CBL-I etiologically related to AIDS.
4912094 MODIFIED LIPOPOLYSACCHARIDES AND PROCESS OF PREPARATION Kent Myers, Alex T Truchot assigned to Ribi ImmunoChem Research Inc Modified lipopolysaccharides, particularly de3-0-acylated monophosphoryl lipid A and de-30-acylated diphosphoryl lipid A, are provided by an alkaline hydrolysis under controlled conditions which removes only the betahydroxymyristic acyl residue that is ester-linked to the reducing-end glucosamine at position 3. The modified products are less endotoxic and maintain their antigenic and immunostimulating properties.
4912136 USES OF A SUBSTITUTED 2-PHENOXYPHENYLACETIC A C I D AS AN IMMUNOSUPPRESSANT DRUG Elizabeth M Wood, Dundee, United Kingdom